DERM - Dermira, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.95
+0.23 (+2.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close9.72
Open9.75
Bid9.84 x 2200
Ask10.23 x 3100
Day's Range9.73 - 10.07
52 Week Range6.00 - 15.48
Volume415,695
Avg. Volume2,158,728
Market Cap533.994M
Beta (3Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Dermira (DERM) Q1 2019 Earnings Call Transcript
    Motley Fool18 days ago

    Dermira (DERM) Q1 2019 Earnings Call Transcript

    DERM earnings call for the period ending March 31, 2019.

  • Did You Manage To Avoid Dermira's (NASDAQ:DERM) Painful 63% Share Price Drop?
    Simply Wall St.18 days ago

    Did You Manage To Avoid Dermira's (NASDAQ:DERM) Painful 63% Share Price Drop?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is doubtless a positive to see that the Dermira, Inc. (NASDAQ:DERM) share price has gained some...

  • Thomson Reuters StreetEvents19 days ago

    Edited Transcript of DERM earnings conference call or presentation 7-May-19 8:30pm GMT

    Q1 2019 Dermira Inc Earnings Call

  • Dermira (DERM) Reports Q1 Loss, Lags Revenue Estimates
    Zacks19 days ago

    Dermira (DERM) Reports Q1 Loss, Lags Revenue Estimates

    Dermira (DERM) delivered earnings and revenue surprises of -13.74% and -6.77%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press19 days ago

    Dermira: 1Q Earnings Snapshot

    The Menlo Park, California-based company said it had a loss of $1.49 per share. The skin condition drug developer posted revenue of $2.5 million in the period, falling short of Street forecasts. Three ...

  • Markit20 days ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Dermira Inc NASDAQ/NGS:DERMView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding DERM are favorable, with net inflows of $898 million. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Dermira (DERM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zackslast month

    Dermira (DERM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Dermira (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zackslast month

    NASDAQ Back Above 8,000

    NASDAQ Back Above 8,000

  • Here's Why Dermira Shot Up 62% in March
    Motley Fool2 months ago

    Here's Why Dermira Shot Up 62% in March

    Results from a mid-stage study with a potential new eczema drug gave investors a reason to cheer.

  • Does The Dermira, Inc. (NASDAQ:DERM) Share Price Fall With The Market?
    Simply Wall St.2 months ago

    Does The Dermira, Inc. (NASDAQ:DERM) Share Price Fall With The Market?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you're interested in Dermira, Inc. (NASDAQ:DERM), then you might want to consider its beta (a measure of share price volat...

  • Dermira (DERM) Catches Eye: Stock Jumps 12%
    Zacks2 months ago

    Dermira (DERM) Catches Eye: Stock Jumps 12%

    Dermira (DERM) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

  • Why Dermira Stock Jumped Again Today
    Motley Fool2 months ago

    Why Dermira Stock Jumped Again Today

    An analyst's upgrade provides another boost to the high-flying biotech stock.

  • Company News For Mar 19, 2019
    Zacks2 months ago

    Company News For Mar 19, 2019

    Companies in the news are: OSTK, FIS, WP, EW and DERM

  • Can Dermira Stock Keep Soaring?
    Motley Fool2 months ago

    Can Dermira Stock Keep Soaring?

    The skincare specialist's experimental eczema treatment hit the mark in mid-stage testing, but what about the road ahead?

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of DERM earnings conference call or presentation 26-Feb-19 9:30pm GMT

    Q4 2018 Dermira Inc Earnings Call

  • Why Dermira Stock Is Soaring More than 80% Today
    Market Realist2 months ago

    Why Dermira Stock Is Soaring More than 80% Today

    Why Dermira Stock Is Soaring More than 80% TodayShare price movements Today, Dermira (DERM) is trading close to $12.85, ~87.87% higher than its previous closing price, with a market capitalization of $292.48 million. The company is trading 114.19%

  • CNBC2 months ago

    Stocks making the biggest moves midday: Facebook, Deutsche Bank, Lumber Liquidators & more

    Boeing shares slipped more than 1.5 percent after The Wall Street Journal reported that federal prosecutors and the Department of Transportation are scrutinizing the development of the company's 737 Max jets. An Ethiopian Airlines flight involving the 737 Max 8 crashed on March 10. Facebook FB — Shares of the social media giant fell more than 3 percent after an analyst at Needham downgraded them to hold from buy.

  • Dermira News: Why DERM Stock Is Skyrocketing Today
    InvestorPlace2 months ago

    Dermira News: Why DERM Stock Is Skyrocketing Today

    Dermira news concerning results from a recent Phase 2b study has DERM stock flying high on Monday.Source: DermiraDermira (NASDAQ:DERM) is reporting that results from its Phase 2b study of using lebrikizumab to treat patients with atopic dermatitis were positive. Atopic dermatitis is a type of skin condition that's main symptom is a red, itchy rash.The Dermira news includes the results from the company testing out three different dosage amounts of lebrikizumab in adult patients with moderate-to-severe atopic dermatitis. All three of these dosage levels were able to meet the primary endpoints of the Phase 2b study.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe Phase 2b study of lebrikizumab involved 280 patients that were 18 or older. These patients were split into four groups for the study. Three of these groups received lebrikizumab at different amounts and the fourth was the placebo group. The treatment was also well tolerated with only mild to moderate adverse events."I have many patients for whom current therapies do not adequately address their needs," Emma Guttman-Yassky, M.D., Ph.D., and a leading investigator in the study, said in a statement . "These data show that lebrikizumab may offer a targeted, effective and well-tolerated therapeutic approach." * 7 Small-Cap Stocks That Make the Grade The positive Dermira news from the Phase 2b study results means that the company is planning to move forward with a Phase 3 study of the drug. It plans to start this next study quickly after getting in contact with U.S. regulators.DERM stock was up 83% as of noon Monday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 of the Best Stocks to Buy Under $10 * 7 Single-Digit P/E Stocks With Massive Upside * 7 Best Quantum Computing Stocks Trading Today As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Dermira News: Why DERM Stock Is Skyrocketing Today appeared first on InvestorPlace.

  • Why Dermira's Shares Are Doubling Today
    Motley Fool2 months ago

    Why Dermira's Shares Are Doubling Today

    Great clinical results for its experimental atopic dermatitis drug provided a huge catalyst for Dermira.

  • TheStreet.com2 months ago

    Dermira Shares Rocket After Successful Phase II Eczema Treatment Study

    shares more than doubled Monday after the group said its new eczema treatment passed a key study in adult patients with moderate-to-severe atopic dermatitis. Dermira, which acquired the development rights to lebrikizumab, from which the treatment is based, from Swiss pharma giant Roche in 2016, said all three doses of lebrikzumab met the primary endpoint with statistical significant in the phase II study. Dermira could use the results to launch a sustained challenger into the global market for atopic dermatitis treatments, which analysts estimate could hit $7.66 billion by 2021.

  • Benzinga2 months ago

    Why Dermira Shares Are Shooting Higher After Last Year's Disappointment

    Dermira reported positive results ahead of the market open Monday from a Phase 2b dose-ranging study of lebrikizumab that is being evaluated for treating adult patients with moderate-to-severe atopic dermatitis. Lebrikizumab is a humanized antibody that binds interleukin-13, or IL-3, inhibiting downstream signaling. Dermira said all three doses evaluated in the dose-ranging study — 125mg every four weeks, 250mg every four weeks and 250mg every two weeks — met the primary endpoint of showing greater improvements in the Eczema Area and Severity, or EASI, index at week 16 compared to placebo.

  • MarketWatch2 months ago

    Dermira shares soar 83% premarket on news of positive trial of dermatitis treatment

    Dermira Inc. shares soared 83% in premarket trade Monday, after the biotech reported positive results in a mid-stage trial of a treatment for moderate-to-severe atopic dermatitis. The Menlo Park, Calif.-based company said a phase 2b trial of Lebrikizumab met its primary endpoint of demonstrating greater improvements in the Eczema Area and Severity Index score (EASI) compared to placebo. The safety profile was consistent with prior studies. Lebrikizumab is an injectable, humanized monoclonal antibody that's designed to specifically block the action of interleukin-13, or IL-13, a substance secreted by certain cells of the immune system that is a central pathogenic mediator in atopic dermatitis. The study involved 280 patients. Atopic dermatitis is a common and severe form of eczema characterized by rashes on the skin that can cover much of the body and include redness, cracking, dryness and intense itching. Dermira shares have fallen 24.8% in the last 12 months, while the S&P 500 has gained 2.6%.